Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Visa (V) reinstated with an Overweight at JPMorgan. 2. Jazz Pharmaceuticals (JAZZ) initiated with a Buy at Goldman. 3. Impax (IPXL) initiated with a Sell at Goldman with analyst Stephan Stewart arguing increasing competition to its largest on-market drug, generic Solaraze and tail risk that Endo's (ENDP) application for a label change on its second largest on-market drug, Opana ER, could result in the eventual removal of Impax's generic. 4. Horizon Pharma (HZNP) initiated with a Buy at Goldman. 5. Waste Connections (WCN) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Baird raised the firm's price target on Visa to $320 from $314 and keeps an Outperform rating on the shares. The firm thinks FQ2 revenue/EPS likely both beat mildly; and they like a lot as long-term compounder.